Flatlander schreef op 3 februari 2020 15:00:
I'm assuming that the KRAS MDx assay is licensed as a CDx regardless of the indication (CRC, NSCLC, etc.). All Pharma gain FDA approval for one indication and then broaden use to other indications. Some Drs. may use a drug off label for a different cancer if it has the same molecular driver. I think the power point is an over simplification for the investors to group the tests into broad disease panels. It will get more blurred as breast and prostate cancer MDx offerings increase.
That said AMG-510 looks like an exciting drug. The ASCO article is a little dated in that it reports Phase Ib clinical results. AMG enrolled and began phase II studies in 2018 so that data is probably already digested and the drug could be into the final stages in the next year or two. from what I can tell, AMG has CDx partnerships with multiple MDx providers including BCART and GH,